Failed IBD trial dents confidence in BMS’ deucravacitinibBristol-Myers Squibb’s hopes of extending the use of its highly-anticipated psoriasis pill deucravacitinib into inflammatory bowel disease (IBD) Share XFailed IBD trial dents confidence in BMS’ deucravacitinibhttps://pharmaphorum.com/news/failed-ibd-trial-dents-confidence-in-bms-deucravacitinib/
BMS’ deucravacitinib psoriasis pill could launch next year after outperforming Amgen’s rivalBristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in Share XBMS’ deucravacitinib psoriasis pill could launch next year after outperforming Amgen’s rivalhttps://pharmaphorum.com/news/bms-deucravacitinib-psoriasis-pill-could-launch-next-year-after-outperforming-amgens-rival/
